Oncotarget

Meta-Analysis:

This article has been corrected. Correction in: Oncotarget. 2018; 9:20220.

An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer

LiLi Yu, Xiaoli Hua, Yu Yang, Ke Li, Qilin Zhang and Lixiu Yu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:81176-81185. https://doi.org/10.18632/oncotarget.20885

Metrics: PDF 941 views  |   HTML 1515 views  |   ?  


Abstract

LiLi Yu1, Xiaoli Hua2, Yu Yang2, Ke Li2, Qilin Zhang2 and Lixiu Yu2

1Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China

2Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China

Correspondence to:

Lixiu Yu, email: ylx120515@163.com

Keywords: ovarian cancer, E-cadherin, prognosis, updated meta-analysis

Received: March 22, 2017     Accepted: August 26, 2017     Published: September 14, 2017

ABSTRACT

Decreased epithelial cadherin (E-cadherin) expression is hypothesized to be related to poor prognosis of ovarian cancer, but the predictive value is still inconsistent. We conducted an updated meta-analysis with a total of 16 studies enrolling 1720 patients to estimate the prognostic value of decreased E-cadherin expression in ovarian cancer. Reduced expression of E-cadherin was significantly associated to poor overall survival (HR = 1.74, 95% CI: 1.40–2.17) and progression-free survival (HR = 1.45, 95% CI: 1.12–1.86) with a large heterogeneity for overall survival. In addition, we found that decreased expression of E-cadherin was significantly correlated with International Federation of Gynecology and Obstetrics grade (HR = 3.74, 95% CI: 2.24–6.23), E-cadherin membranous (HR = 1.47, 95% CI: 1.01–2.14), pathologic grade (HR = 1.41, 95% CI: 1.01–1.97), residual tumor size (HR = 2.72, 95% CI: 1.99–3.72), and surgery (HR = 3.21, 95% CI: 1.19–8.67). Our finding suggests that decreased E-cadherin expression may be a predictor of poor ovarian cancer prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20885